BSEM-003

BSEM-003 is an investigational **amnion derived mesenchymal stem cell therapy** being developed by BioStem Technologies as a potential treatment for **acute respiratory distress syndrome**. Publicly available pipeline references describe it as a perinatal tissue derived regenerative biologic composed of mesenchymal stem cells from amnion, but do not provide a validated molecular target, dosing form, route, or detailed clinical pharmacology. Based on the modality, its intended therapeutic rationale is likely immunomodulatory and tissue reparative activity in inflammatory lung injury rather than single-target receptor pharmacology. Available evidence indicates the program remained **preclinical or pending/unknown development status**, with no clear evidence of regulatory approval or branded commercialization.

Other names

amnion derived MSCs therapy